Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Risk of Progression to Endometrial Carcinoma in Premenopausal Women with Endometrial Hyperplasia

Critical Distinction and Management

  • The presence or absence of atypia is the single most important prognostic factor, with atypia carrying a significantly higher risk of progression to carcinoma, according to the American College of Obstetricians and Gynecologists 1

Management Implications for Premenopausal Women

  • Hormonal treatment options, including megestrol acetate, medroxyprogesterone, or levonorgestrel-releasing intrauterine devices, are recommended by the National Comprehensive Cancer Network 2, 3
  • Close monitoring with endometrial sampling every 3-6 months is recommended during conservative management, as suggested by the National Comprehensive Cancer Network 2, 3

Risk Factors That Modify Progression Risk

  • Unopposed estrogen exposure increases endometrial cancer risk 10-30 fold if continued for 5+ years, according to the European Society for Medical Oncology 4, 5, 6